QRG Capital Management Inc. Has $6.92 Million Stock Holdings in Sanofi (NASDAQ:SNY)

QRG Capital Management Inc. lessened its stake in Sanofi (NASDAQ:SNY) by 5.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 143,510 shares of the company’s stock after selling 8,896 shares during the quarter. QRG Capital Management Inc.’s holdings in Sanofi were worth $6,921,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Synergy Asset Management LLC acquired a new position in shares of Sanofi during the 4th quarter worth $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. Sierra Ocean LLC acquired a new position in shares of Sanofi during the 4th quarter worth $44,000. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi during the 4th quarter worth $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Price Performance

NASDAQ SNY opened at $54.47 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $51.65 and a 200 day simple moving average of $52.61. The company has a market cap of $138.24 billion, a P/E ratio of 21.88, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SNY. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.